Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)

The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban (DOACs) offers some major advantages over warfarin and other vitamin K antagonists (VKAs). One advantage is the possibility to use a fixed dose in normal-weight patients, overweight patients and patients with ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Mocini, David, Di Fusco, Stefania Angela, Mocini, Edoardo, Donini, Lorenzo Maria, Lavalle, Carlo, Di Lenarda, Andrea, Riccio, Carmine, Caldarola, Pasquale, De Luca, Leonardo, Gulizia, Michele Massimo, Oliva, Fabrizio, Gabrielli, Domenico, Colivicchi, Furio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468506/
https://www.ncbi.nlm.nih.gov/pubmed/34575306
http://dx.doi.org/10.3390/jcm10184185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468506/
https://www.ncbi.nlm.nih.gov/pubmed/34575306
http://dx.doi.org/10.3390/jcm10184185

Ejemplares similares